Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Obicetrapib Capsule and Tablet Formulations
NCT02523391Phase 1Completed
- Sponsor
- Xention Ltd.
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of obicetrapib in dyslipidemia (2 arms), sponsored by Xention Ltd. Primary endpoints: Area under the plasma concentration versus time curve at 72 hours and Peak Plasma Concentration at 72 hours. Started Jul 2015; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02523391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523391.